Australian doctors are now investigating a seventh case of acute liver toxicity linked to black-market peptides sold as retatrutide, the experimental weight-loss compound still in clinical trials and patented exclusively by Eli Lilly. All seven patients are in Victoria, and the localized clustering has authorities suspecting something specific: not the compound itself, but a contaminated batch moving through the counterfeit supply chain.
Dr. Marie Sinclair, a liver transplant specialist who has treated several of the affected patients, said the injuries typically appeared within weeks of a second dose, with patients becoming jaundiced and seriously unwell. She has since commissioned independent testing of the counterfeit product to identify what, exactly, patients were actually taking. Australia's Therapeutic Goods Administration (TGA) has reached a similar conclusion from a different angle: its chief medical advisor said the geographic concentration of cases points to "a batch problem" rather than a risk inherent to every unit sold under that label. Crucially, the TGA emphasized that there is no such thing as a "safe" unapproved peptide in this market, the risk applies broadly, not just to the specific batch under investigation.
The scale of the enforcement response underscores how large this problem has become. The TGA reports it has destroyed more than 94,500 unapproved peptide products this year in cooperation with Australian Border Force, and authorities recently seized more than $120,000 in illicit peptide and steroid products tied to a social media influencer, on top of a $2 million seizure of similar products earlier this year. Eli Lilly, for its part, reiterated that any retatrutide sold online is "unapproved, unverified and simply not worth the risk," a pointed reminder that the compound circulating on gray-market channels bears no confirmed relationship to the molecule the company is actually studying in trials.
What makes this story different from a typical regulatory update is that it isn't hypothetical. These are seven documented hospitalizations traced back to a supply chain with no chain of custody, no verified manufacturing standards, and no batch-level accountability. It's a concrete illustration of a principle that gets repeated often in this industry but is easy to treat as boilerplate: a label on a vial tells you nothing about what's actually inside it. Only independent, batch-specific testing does that.
Source: ABC News (Australia), "Doctors fear possible contaminated counterfeit peptide batch after seventh case of acute liver damage," Aug. 24, 2026.
